Tuberculosis and protozoal infections in transplanted patients;Tuberculosis e infecciones protozoarias en el paciente sometido a trasplante

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue SUPPL. 2, 1997, Pages 57-68

  Aguado, José M ^a   Herrero, José A ^a   Lumbreras, Carlos ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIMONY DERIVATIVE; PYRIMETHAMINE; RIFAMPICIN; SULFADIAZINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

HUMAN; LEISHMANIA; MALARIA; PARASITOSIS; PNEUMOCYSTIS CARINII; PROTOZOON; REVIEW; SPAIN; TOXOPLASMA GONDII; TRANSPLANTATION; TRYPANOSOMA; TUBERCULOSIS;

ANTIPROTOZOAL AGENTS; ANTITUBERCULAR AGENTS; HUMANS; INFECTION CONTROL; POSTOPERATIVE COMPLICATIONS; PROTOZOAN INFECTIONS; TRANSPLANTATION; TUBERCULOSIS;

EID: 0030975805     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (171)

1. Lloveras J, Phillip K, Peterson RL, Simmons RL, Najarian JS. Mycobacterial infections in renal trasplant recipients. Arch Intern Med 1982; 142: 888-892.
2. Quinibi WY, Al-Sibai MB, Taher S, Harder EJ, De Vol E, Al-Furayh O et al. Mycobacterial infection after renal trasplantation -report of 14 cases and review of the literature. Q J Med 1990; 77: 1.039-1.060.
3. Higgins RM, Cahn AP, Porter D, Richardson AJ, Mitchell RG, Hopkin JM, Morris PJ. Mycobacterial infections after renal trasplantation. Q J Med 1991; 78: 145-153.
4. Koselj M, Buturovic J, Malovrth M. Tuberculosis in renal allograft recipients. Transpl Proc 1992; 24: 1.909-1.910.
5. Riska H, Grönhagen-Riska C, Ahonen J. Tuberculosis and renal allograft transplantation. Transpl Proc 1987; 19: 4.096-4.097.
6. Higgins RSD, Kusne S, Reyes J, Yousem S, Gordon R, Van Thiel R et al. Mycobacterium tuberculosis after liver transplantation: management and guidelines for prevention. Clin Transplantation 1992; 6: 81-90.
7. Delaney V, Sumrani N, Hong JH, Sommer B. Mycobacterial infections in renal allograft recipients. Transpl Proc 1993; 25: 2.288-2.289.
8. Hall CM, Willcox PA, Swanepoel CR, Kahn D, Van Zyl-Smit R. Mycobacterial infection in renal trasplant recipients. Chest 1994; 106: 435-439.
9. John GT, Vincent L, Jeyascelan L, Jacob CK, Shastry JCM. Cyclosporine immunosuppression and mycobacterial infections. Transplantation 1994; 58: 247-249.
10. Stöblen F, Neuhaus R, Neumann K, Grauhan O, Bechstein WO, Klein E et al. Tuberculosis in liver transplant recipients: recurrence after transplantation? Transpl Proc 1994; 26: 3.604-3.605.
11. Wong LL, Levin BS, Collins GM, Bry WI. Unusual manifestations of tuberculosis in cyclosporine-treated renal transplant recipients. Clin Transpl 1973; 7: 18-24.
12. Malhotra KK, Dash SC, Dhawan IK, Bhuyan UN, Gupta A. Tuberculosis and renal transplantation-observations from an endemic area of tuberculosis. Postgrad Med J 1986; 62: 359-362.
13. Higgins RM, Cahn AP, Porter D, Richardson AJ, Mitchell RG, Hopkin JM, Morris PJ. Mycobactcrial infections after renal transplantation. Q J Med 1991; 78: 145-153.
14. Dromer C, Nashef SAM, Velly JF, Martigne C, Couraud L. Tuberculosis in trasplanted lungs. J Heart Lung Transplant 1993; 12: 924-927.
15. Sundberg R, Shapiro R, Darras F, Jensen C, Scantlebury V, Jordan M et al. A tuberculosis outbreak in a renal transplant program. Transpl Proc 1991; 23: 3.091-3.092.
16. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994; 58: 301-306.
17. Naqvi SA, Hussain M, Askari H, Hashmi A, Hussain Z, Hussain I et al. Is there a place for prophylaxis against tuberculosis following renal transplantation? Transpl Proc 1992; 24: 1.912.
18. De March P. Tuberculosis y SIDA. Situación en España y perspectivas. Rev Clin Esp 1990; 186: 365-368.
19. Roberts G, Koneman E, Yoo KM. Mycobacterium. En: Balows A, Hausler WJ, Hermann KL, Isenberg HD, Shadomy HJ, eds. Manual of clinical microbiology, 5a. ed. Washington, DC: American Society for Microbiology, 1991; 304-339.
20. García-Leoni ME, Martin-Scapa C, Rodeño P, Valderrábano F, Moreno S, Bouza E. High incidence of tuberculosis in renal patients. Eur J Clin Microbiol Infect Dis 1990; 9: 283-285.
21. Muñoz P, Palomo J, Muñoz R, Rodríguez-Créixems M, Peláez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21: 398-402.
22. Coutts IJ, Jegarajah S, Stark JE. Tuberculosis in renal transplant recipient. Br J Dis Chest 1979; 73: 141-148.
23. Sinnott JT, Emmanuel PJ. Mycobactcrial infections in the transplant patient. Semin Respir Infect 1990; 5: 65-73.
24. Neff TA, Hudgel DW. Miliary tuberculosis in a renal transplant recipient. Am Rev Resp Dis 1973; 108: 677-678.
25. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152: 374-376.
26. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983; 5: 216-226.
27. Delaney V, Sumrani N, Hong JH, Sommer B. Mycobacterial infections in renal allograft recipients. Transplant Proc 1993; 25: 2.228-2.289.
28. Torre-Cisneros J, Villanueva JL, Gutiérrez-Aroca J, Kindelán JM, Prada JL, Jurado R et al. Importance of surveillance mycobacterial cultures after transplantation [resumen LM87]. 35th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco: American Society for Microbiology, 1995; 342.
29. Langhoff E, Madsen S. Rapid metabolism of cyclosporine and prednisone in kidney transplant patient receiving tuberculostatic treatment [carta]. Lancet 1983; 2: 1.031.
30. Offermann G, Keller F, Molzahn M. Low cylosporine A blood levels and acute graft rejection in a renal transplant recipient during rifampin treatment. Am J Nephrol 1985; 5: 385-387.
31. Buffington GA, Domínguez JH, Piering WF, Hebert LA, Kauffman HM Jr, Lemann J Jr. Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA 1976; 236: 1.958-1.960.
32. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shuṁway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313-314.
33. Chan GL, Sinnot JT, Emmanuel PJ, Cyanle S, Weinstein SS. Drug interactions with cyclosporine: focus on antimicrobial agents. Clin Transpl 1992; 6: 141-153.
34. Daniels NJ, Dover JS, Schachter RK. Interaction between cyclosporin and rifampin [carta]. Lancet 1984; 2: 639.
35. Al-Sulaiman MH, Dhar JM, Al-Khader AA. Successful use of rifampin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine.Transplantation 1990; 50: 597-598.
36. Dummer JS. Infectious complications of heart-lung transplantation. En: Cooper DCC, ed. Heart and Lung Replacement. Londres: Medical and Technical Press Ltd., 1993; 734-762.
37. Abbott MR, Smith DD. Mycobacterial infections in immunosuppressed patients. Med J Aust 1981; 1: 351-353.
38. Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Am Rev Respir Dis 1991; 143: 1.386-1.405.
39. American Thoracic Society. Medical Section of the American Lung Association: treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986; 134: 355-363.
40. Al Batata M. Pulmonary tuberculosis in a renal transplant recipient. JAMA 1977; 237: 1.465.
41. Mullerova M, Pekarck J, Nouzak J. Immunosuppression and experimental tuberculosis. Biomed 1974; 20: 390-397.
42. American Thoracic Society. Preventive therapy of tuberculosis infection. Am Rev Respir Dis 1974; 110: 371-374.
43. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JCM. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994; 57: 1.6S3-1.6S4.
44. Thomas PA Jr, Mozes MF, Jonasson O. Hepatic disfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979; 114: 597-599.
45. Thomas PA, Manko MA. Chemoprophylaxis for the prevention of the tuberculosis in the immunosupressed renal allograft recipient. Transplantation 1975; 20: 76-77.
46. John GT, Thomas PP, Thomas M, Jeyascclan L, Jacob CK, Shastry JCM. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994; 57: 1.683-1.684.
47. Moreno S, Baraia-Etxaburu J, Bouza E, Parras F, Pérez-Tascón M, Millares P et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993; 119: 194-198.
48. Kusne S, Irish W, Geary K, Ondick L, Rakela J, Fung J. Anergy panel and purified protein derivative skin testing arc poor tuberculosis screening methods in adult liver candidates [resumen j33]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: American Society for Microbiology, 1995; 342.
49. Fishman JA. Miniature swine as organ donors for man: strategies for prevention of xenotransplant-associated infections. Xenotransplantation 1994; 1: 47-57.
50. Fishman JA. Pneumocystis carinii pneumonia. En: Fishman AP, ed. Update: Pulmonary Diseases and Disorders. Nueva York: McGraw-Hill, 1992; 263-286.
51. Hughes WT. Pneumocystis carinii pneumonitis. Nueva York: CRC Press, 1987.
52. Hardy AM, Wajszczuk CP, Suffredini AF et al. Pncumocystis carinii pneumonia in renal-trasplant recipients treated with cyclosporine and steroids. J Infect Dis 1984; 149: 143-147.
53. Kusne S, Dummer JS, Singh N, Iwatsuki L, Makouka C, Esquivel AG. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine 1988; 67: 132-143.
54. Young LS. Clinical aspects of Pneumocystis carinii in man: epidemiology, clinical manifestations, diagnostic approaches and sequelae. En: Young LS, ed. Pneumocystis carinii pneumonia. Nueva York: Dekker, 1984; 139-174.
55. Hendley JO, Weller TH. Activation and transmission in rats of infection with Pneumocystis. Proc Soc Exp Biol Med 1971; 137: 1.401-1.401.
56. Wong B. Parasitic infections in immunocompromised host. Am J Med 1984; 76: 479-486.
57. Chave JP, David S, Wauters JP et al. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant recipients. AIDS 1991; 5: 927-932.
58. Perera DR, Westerii KA, Johnson HD et al. Pneumocystis carinii pneumonia in a hospital for children. JAMA 1970; 214: 1.070-1.078.
59. Singer C, Armstrong D, Rosen PP et al. Pneumocystis carinii pneumonia, a cluster of eleven cases. Ann Intern Med 1977; 82: 772-777.
60. Meuwissen JHET, Tauber L, Leenwenberg ADEM et al. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis 1977; 136: 43-49.
61. Bartlett MS, Fishman JA, Queener SF et al. Pneumocystis carinii: improved models and study efficacy of drugs for the treatment or prophylaxis of Pneumocystis pneumonia. Exp Parasitol 1990; 70: 100-106.
62. Ballardie FW, Winearls CG, Williams G. Cylosporin and steroids in renal transplantation: risk of Pneumocystis pneumonia? Lancet 1984; 2: 638-639.
63. Hardy AM, Wajszczk CP, Suffredini AF et al. Pneumocystis carinii pneumonia in renal transplant patients treated with cyclosporin and steroids. J Infect Dis 1984; 149: 143-147.
64. Dummer JS. Infectious complications of transplantation. En: Brest AN, ed. Cardiovascular Clinics. Filadelfia: Davis, 1990; 163-178.
65. Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart trasplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209-216.
66. Paya CV, Hermans PE, Washington JA Jr et al. Incidence, distribution, and outcome episodes of infection in 100 orthotopic liver transplantations. May Clin Proc 1989; 64: 555-564.
67. Pahissa A. Infecciones protozoarias. En: Cuervas-Mons V, JL del Castillo-Olivares, eds. Introducción al trasplante de órganos y tejidos. Madrid: Editorial Arán, 1994; 395-412.
68. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin N Am 1995; 9: 1.005-1.043.
69. Walzer PD, Pert DP, Krogstad DJ et al. Pneumocystis carinii pneumonia in the United States: epidemiologic, diagnostics, and clinical features. Ann Intern Med 1974; 80: 83-93.
70. Gryzan S, Paradis IL, Zeevi A et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Am Rev Respir Dis 1988; 137: 1.268-1.274.
71. Wharton JM, Coleman DL, Wofsy CB et al. Trimethroprin-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 37-44.
72. Walzer PD. Pneumocystis carinii pneumonia. Nueva York: Marcel Dekker, 1994.
73. Ognibene FP, Shelhamer J, Gil V et al. The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis 1984; 129: 929-932.
74. Bigby PD, Margolskee D, Curtis J et al. Usefulness of induced sputum in diagnosis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1986; 133: 515-518.
75. Waldron MA, Fishman JA. Pneumocystis carinii: advances in diagnosis. Clin Microbiol News 1992; 14: 161-166.
76. Wakefield AE, Pixley FJ, Banchi S et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990; 336: 451-453.
77. Coleman DL, Hattner RS, Luce JM et al. Correlation between gallium lung scans and fiberoptic bronchoscopy in patients suspected Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome. Am Rev Respir Dis 1984; 130: 1.166-1.169.
78. Sattler FR, Remington JS. Intravenous trimethoprim-sulfamethoxazole therapy for Pneumocystis carinii pneumonia. Am J Med 1981; 70: 1.215-1.221.
79. Young LA. Trimethoprim-sulfamethoxazole in the treatment of adults with pneumonia due to Pneumocystis carinii. Rev Infect Dis 1982; 4: 608-613.
80. Hughes WT, Feldman S, Chaudhary SC et al. Comparison of pentamidine isethionate and trimethoprim-sulfametoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978; 92: 285-291.
81. Siegel SE, Wolff LJ, Bachner RL et al. Treatment of Pneumocystis carinii, pneumonitis Am J Dis Child, 1984; 138: 1.051-1.054.
82. Bozzette SA, Sattler FR, Chiu J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1.451-1.457.
83. Gagnon S, Boota AM, Fischl MA et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double blind, placebo controlled trial. N Engl J Med 1990; 323: 1.444-1.450.
84. Rifkin D, Marchioro TL, Waddel WR. Infectious diseases associated with renal homotransplantation. JAMA 1964; 189: 391-407.
85. Kusne S, Dummer JS, Ho M et al. Self limited toxoplasma parasitemia after liver transplantation. Transplantation 1987; 44: 457-458.
86. Stinson E, Bieber CP, Grieff RB et al. Infectious complications after cardiac transplantation in man. Ann Intern Med 1971; 74: 22.
87. Dummer JS, Montero CC, Griffith BP et al. Infections in heart-lung transplant recipients. Transplantation 1986; 41: 725-729.
88. Hofflin JM, Potasman I, Baldwin JL et al. Infectious complications in heart transplants recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209-216.
89. Luft BJ, Naot Y, Araujo FG et al. Primary and reactivated toxoplasmosis infection in patients with cardiac transplants. Ann Intern Med 1983; 99: 27-31.
90. Ryning FW, McLeod R, Maddox JC et al. Probable transmission of Toxo-plasma gondii by organ transplantation. Ann Intern Med 1979; 90: 47-49.
91. Cabrol C, Solis E, Muncretto C et al. Orthotopic transplantation after implantation of a Jarvik 7 total artificial heart. J Thorac Cardiovasc Surg 1989; 97: 342-356.
92. Derouin F, Debure A, Godeau E et al. Toxoplasma antibody liters in renal transplant recipients. Pretransplant evolution and post-transplant follow up of 73 patients. Transplantation 1987; 44: 515-518.
93. Speirs GE, Hakim TG, Calne RY et al. Relative risk of donor acquired Toxoplasma gondii in heart, liver and kidney transplant recipients. Clin Transplant 1988; 2: 257-260.
94. Remington JS, Cavanaugh EN. Isolation of the encysted of Toxoplasma gondii from skeletal muscle and brain. N Engl J Med 1965; 273: 1.308-1.310.
95. Gaines JD, Araujo FG, Krahenbuhl JL et al. Simplified in vitro method for measuring delayed type hypersensitivity to latent celular infection in man (toxoplasmosis). J Immunol 1972; 109: 179-182.
96. Jones TC, Len L, Hirsch JG. Asessment in vitro of immunity againsts Toxoplasma gondii. J Exp Med 1975; 141: 406.
97. Thomson AW, Smith SWG, Chappel LH. Cyclosporin A: immune suppressant and antiparasitic agent. Parasitol Today 1986; 2: 288-290.
98. Suzuki Y, Orellana MA, Schreiber RD et al. Interferon gamma: the major mediator of resistance againsts Toxoplasma gondii. Science 1988; 240: 516-518.
99. Luft BJ, Kansas G, Engelman EG et al. Functional and quantitative alterations in T lymphocyte subpopulations in acute toxoplasmosis. J Infect Dis 1984; 150: 761.
100. Araujo FG. Depletion of L3T4+(CD4+) T lymphocytes prevents development of resistance to Toxoplasma gondii in mice. Infect Immun 1991; 59: 1.614-1.619.
101. McCabe RE, Luft BJ, Remington JS. The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro. Transplantation 1986; 41: 611-615.
102. O'Connor CR, Frenkel JK. Dangers of steroid treatment in toxoplasmosis. Arch Opthalmol 1976; 94: 213.
103. Luft BJ, Naot Y, Araujo FG et al. Primary and reactivated toxoplasma infection in patients with cardiac trasplant clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med 1983; 99: 27-31.
104. Michaels MG, Wald ER, Ficker FJ et al. Toxoplasmosis in pediatric recipients of heart transplants. Clin Infect Dis 1992; 14: 847-851.
105. Raisanen S. Toxoplasmosis transmitted by blood transfusions. Transfusion 1978; 329-332.
106. Rose AG, Uys CJ, Noxitsky D et al. Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantations. Arch Pathol Lab Med 1983; 107: 368-373.
107. Ryniig FW, McLeod R, Madox JC et al. Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 1979; 84: 47-49.
108. Siegel S, Lunde M, Celderman A et al. Transmission of toxoplasmosis by leukocyte transfusion. Blood 1971; 37: 388-394.
109. Harkim M. Toxoplasmosis in cardiac transplantation. BMJ 1986; 92: 1.108.
110. Fishman JA. Pneumocystis carinii and parasitic infections in the immunocompromised host. En: Rubin RH, Young LS, eds. Clinical Approach to Infection in the Compromised Host. Nueva York. Plenum Medical Book Co., 1994; 275-334.
111. Derouin F, Devergie A, Auber P et al.Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis 1992; 15: 267-270.
112. Colino A, Dutican J, Zeluff B et al. Leishmaniasis in a heart transplant patient. J Heart Lung Transplant 1992; 11: 820-823.
113. Wreghit TG, Harkin M, Gray JJ et al. Toxoplasmosis in heart lung transplant recipients. J Clin Pathol 1989; 42: 194-199.
114. Brooks UG, Sharna SD, Remington JS. Detection of Toxoplasma gondii antigens by dotimmunobinding technique. J Clin Microbiol 1985; 21: 113-116.
115. Estruch R, Casademon J, Urbano-Marquez A et al. Value of positive serologic findings for toxoplasmosis in the immunocompromised host. Arch Intern Med 1984; 144:660.
116. Shepp DH, Hackman RC, Conely FK et al. Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann Intern Med 1985; 103: 218-221.
117. Derouin F, Mazeron MC, Garin YJP. Comparative study of tissue culture and mouse inoculation methods for demonstration of Toxoplasma gondii. Clin Microbiol 1987; 25: 1.597-1.600.
118. Bretagne S, Costa JM, Vidaud M et al. Detection of Toxoplasma gondii by competitive DNA amplification of bronchoalveolar ravage sample. J Infect Dis 1993; 168: 1.585-1.588.
119. Bozzette SA, Sattler FR, Chiu J et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1.451-1.457.
120. Gazzinelli RT, Hakim F, Hieny S et al. Synergistic role of CD4+ and CD8+T lymphocytes in IFN-gamma production and protective immunity induced by and attenuated Toxoplasma gondii vaccine. J Immunol 1991; 146: 286-292.
121. Aguado JM, Plaza J, Escudero A. Visceral leishmaniasis in renal-transplant recipient. J Infect 1986; 13: 301-302.
122. Aguado JM, Gómez J, Figuera A et al. Visceral leishmaniasis complicating acute leukemia. J Infect 1983; 7: 272-274.
123. Fernández-Guerrero ML, Aguado JM, Buzon L et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83: 1.098-1.102.
124. Montalbán C, Martínez-Fernández R, Calleja JL et al. Visceral leishmaniasis (KalaAzar) as an opportunistic infection in patients infected with the human immunodeficiency virus in Spain. Rev Infect Dis 1989; 11: 655-660.
125. Pearson RD, Wheeler DA, Harrison LH et al. The immunobiology of leishmaniasis. Rev Infect Dis 1983; 5: 907-927.
126. Nabors CS, Farrell JP. Site-specific immunity to Leishmania major in SWR mice: the site of infection influences susceptibility and expression of the antileishmanial immune response. Infect Immun 1994; 62: 3.655-3.662.
127. Broeckaert A, Michielscn P, Vandepitte J. Fatal leishmaniasis in renal-transplant patient. Lancet 1979; 2: 740-741.
128. Horber FF, Lerut JP, Reichen J et al. Visceral leishmaniasis after orthotopic liver transplantation: impact of persistent splenomegaly. Transpl Int 1993; 6: 55-57.
129. Pampiglione S, Mason-Bahr PEC, Giungu F et al. Studies on Mediterranean leishmaniasis 2. Asymptomatic cases of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1974; 68: 447-453.
130. Badaró R, Rocha H, Carvalho EM et al. Visceral leishmaniasis: an opportunistic microbe associated with progressive disease in three inmunocompromised patients. Lancet 1986; 1: 647-648.
131. Senaldi G, Cadeo G, Carnevalle G et al. Visceral leishmaniasis as an opportunistic infection. Lancet 1986; 1: 1.094.
132. Ma DDF, Concannon AJ, Hayes J. Fatal leishmaniasis in renal-transplant recipient. Lancet 1979; 2: 311-312.
133. Broeckaert A, Michielsen P, Vandepitte J. Fatal leishmaniasis in renal-transplant patient. Lancet 1979; 2: 740-741.
134. Lamas S, Orte L, Parras F et al. Non fatal leishmaniasis in a renal transplant recipient. Nephron 1987; 45: 71.
135. Blont ER, Hartman R, Nernoff J. Kala-azar as a cause of disseminated intravascular coagulation. Clin Pediatr (Phila) 1980; 19: 139-140.
136. Harrison LH, Naidu TG, Drew JS et al. Reciprocal relationship between undernutrition and the parasitic disease visceral leishmaniasis. Rev Infect Dis 1986; 8: 447-453.
137. Cerf BJ, Jones TC, Badaro R et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987; 156: 1.030-1.033.
138. Wong B. Parasitic infections in immunocompromised hosts. Am J Med 1984; 76: 479-486.
139. Chunge CN, Gachihi G, Mulgai R et al. Visceral leishmaniasis unresponsive to antimonial drugs. Successful treatment using a combination of sodium stilbogluconate plus allopurinol. Trans R Soc Med Hyg 1985; 79: 715-718.
140. Halim MA, Alfurayh O, Kalin ME et al. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazolo in a renal trnasplant recipient after the occurrence of pancreatitis due to stibogluconate. Clin Infect Dis 1993; 16: 397-399.
141. Veiga JPR, Wolff ER, Sampaio RN et la. Renal tubular dysfunction in patients treated with pentavalents antimonials. Lancet 1983; 2: 569.
142. Cockburn ITR, Krupp P. An appraisal of drug interactions with sandimmun. Transplant Proc 1989; 21: 3.845-3.850.
143. Levafour G, Pierce J, Frame J. Renal transplant associated malaria. JAMA 1980; 244: 1.820-1.821.
144. Crafa F, Gugenheim J, Fabiani P et al. Possible transmission of malaria by liver transplantation. Transplant Proc 1991; 23: 2.664.
145. Cantarovich F, Vazquez M, Duro García W et al. Special infections in organ transplantation in South America. Transplant Proc 1992; 24: 1.902-1.908.
146. Aydin H, Doppl W, Battmann A et al. Opportunistic Strongyloides stercoralis hyperinfection in lymphoma patients undergoing chemotherapy and/or radiotherapy. Report of a case and review of the literature. Acta Oncol 1994; 33: 78-80.
147. Centa RM, Miles P, Fields K. Opportunistic Strongyloides stercolaris infection in lymphoma patients. Report of a case and review of the literature. Cancer 1989; 63: 1.407-1.411.
148. Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercolaris in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104: 119-122.
149. DeVault CA Jr, King JW, Rohr MS et al. Opportunistic infections with Strongyloides stercolaris in renal transplantation. Rev Infect Dis 1990; 12: 653-671.
150. German JC, Flores JFI, Chiesura G et al. Fatal strongyloidiasis in an immunodepressed patient following renal transplantation. Rev Hosp Clin Fac Med Sao Paulo 1992; 47: 31-33.
151. Meyers AM, Shapiro DJ, Milne FJ et al. Strongyloides stercolaris hyperinfection in a renal allograft recipient. S Afr Med J 1976; 50: 1.301-1.302.
152. Stone WJ, Schaffner W. Strongyloides infections in transplant recipients. Semin Respir Infect 1990; 5: 58-64.
153. Scoggin CH, Call NB, Cruz T et al. Acute respiratory failure due to disseminated strongyloidiasis in a renal transplant recipient: fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med 1966; 275: 1.093-1.096.
154. Culeria AS, Khawand N, Ali A et al. Experience with schistosomiasis in renal transplantation. Urology 1992; 40: 400-404.
155. Shokeir AA, Bakr MA, Diasty TA et al. Urological complications following live donor kidney transplantation: effect of urinary schistosomiasis. Br J Urol 1992; 70: 247-251.
156. Tewari A, Ward RG, Kumar S. Urological complications following live donor kidney transplantation: effect of urinary schistosomiasis. Br J Urol 1993; 71: 364.
157. Sobh MA, El Agrotdy AE, Motistafa FE et al. Impact of schistosomiasis on patient and graft outcome after kidney transplantation. Nephrol Dial Transplant 1992; 7: 858-864.
158. Stolf N, Higushi L, Bocchi E et al. Heart transplantation in patients with Chagas disease cardiomyopathy. J Heart Transplant 1987; 6: 307-311.
159. Bocchi EA, Bellotti G, Uip D et al. Long-term follow-up after heart transplantation in Chagas' disease. Transplant Proc 1993; 25: 1.329-1.330.
160. Cantavorich F, Davalos M, Cantarovich M et al. Should cadaveric donors with positive serology for Chagas' disease be excluded from kidney transplantation. Transplant Proc 1991; 23: 1.367-1.368.
161. Cantavorich F, Saucedo G, Cantavorich M et al. Should cadaveric donors with positive serology for Chagas' disease be excluded for kidney transplantation. Transplant Proc 1990; 22: 273.
162. Aulet F, Riarte A, Pattin M et al. Chagas' disease and kidney transplantation. Transplant Proc 1991; 23: 2.653.
163. De Arteaga J, Massari PU, Calli B et al. Renal transplantation and Chagas' disease. Transplant Proc 1992; 24: 1.900-1.901.
164. Figueiredo JF, Fiorillo AM, Ferraz AS. Longitudinal study of the indirect inmunofluorescence and complement fixation test for diagnosis of Chagas' disease in immunosuppressed patients submitted to renal transplantation. Rev Soc Bras Med Trop 1993; 26: 211-214.
165. López-Blanco OA, Cavalli NH, Jasovich A et al. Chagas' disease and kidney transplantation-follow-up of nine patients for 11 years. Transplant Proc 1992; 24: 3.089-3.090.
166. Villalba R, Fornes G, Alvarez MA et al. Acute Chagas' disease in a recipient of a bone marrow transplant in Spain: case report. Clin Infect Dis 1992; 14: 594-595.
167. Thombo S, Passalogna W, Van Canwelayh R et al. Enfermedad de Chagas en trasplantados renales. Rev Med Chil 1989; 117: 18-22.
168. Sobrino JM, Pulpon LA, Crespo MG et al. Heart transplantation in a patient with liver hydatidosis. J Heart Lung Transplant 1993; 12: 531-533.
169. Moreno-González E, Loinaz Segurola C, García Ureña MA, García I, Gómez Sanz R, Jiménez Romero C et al. Liver transplantation for Echinococcus granulosus hydatid dosease. Transplantation 1994; 58: 797-800.
170. Bresson-Hadni S, Miguet JP, Lenys D et al. Recurrence of alveolar echinococcosis in the liver graft after liver transplantation. Hepatology 1992; 16: 279-280.
171. Varela-Diaz VM, Williams JF, Coltorti JF, Coltori EA, Williams CS. Survival of cysts of Echinococcus granulosus after transplant into homologous and heterologous hosts. J Parasitol 1974; 60: 608-612.